Skip to main content

Clinical trial DESTINY- Breast12

An Open-Label, Multinational, Multicenter, Phase 3b/4 Study of Trastuzumab Deruxtecan in Patients With or Without Baseline Brain Metastasis With Previously Treated Advanced/Metastatic HER2 Positive Breast Cancer (DESTINY- Breast12)

Organ Breast
Trial status Trial open for recruitment
Trial type
Interventional with experimental drug
Phase Trial phase 3/4
Academic trial Non
Sponsor AstraZeneca
EudraCT Identifier 2020-005048-46
Last update